Literature DB >> 30672276

Chemical Reactivity of Aloe-Emodin and Its Hydroxylation Metabolites to Thiols.

Xu Wang1, Xin Xin1, Ying Sun1, Lizhu Zou1, Hui Li1, Yufei Zhao1, Ruihong Li1, Ying Peng1, Jiang Zheng1,2.   

Abstract

Aloe-emodin (AE), an anthraquinone derivative, is a bioactive ingredient isolated from rhubarb which is used to treat inflammatory illnesses in China and many other countries in Asia. AE has shown a wide range of pharmacological effects. Recent studies showed that exposure to AE could cause DNA damage and cytotoxicity. The goals of the present study are aimed at (1) exploration of oxidative metabolism pathways of AE, (2) identification of P450 enzymes which respond the hydroxylation of AE, and (3) determination of electrophilicity of AE and its oxidative metabolites. Two hydroxylation metabolites (M1 and M2) and four GSH conjugates (M3-M6) were found in incubations consisting of AE, rat or human liver microsomes, and NADPH supplemented with GSH. Conjugates M3 and M4 came from AE itself, and M5 and M6 originated from M1 and M2 individually. M1 and M2 (5-hydroxy aloe-emodin) and M3-M6 were also detected in rat primary hepatocytes after exposure to AE. Additionally, biliary M3, M4, and M6 were detected in rats given AE. Urinary M1, M2, and M7 (a NAC conjugate) were observed in animals administered AE. Recombinant P450 enzyme incubations illustrated that hydroxylation of AE was primarily catalyzed by P450 1A2, 3A4, and 3A5. The metabolism investigation will help us to better understand the biochemical mechanisms of cytotoxicity induced by AE.

Entities:  

Year:  2019        PMID: 30672276     DOI: 10.1021/acs.chemrestox.8b00248

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  1 in total

1.  Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.

Authors:  Bo Li; Xin Zhao; Lei Zhang; Wen Cheng
Journal:  Front Oncol       Date:  2021-02-09       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.